145 related articles for article (PubMed ID: 21252454)
1. Adverse effects after HAART Initiation in resource-limited settings: a prospective study from Mysore, India.
Sreenivasan S; Dasegowda V
J Infect Dev Ctries; 2010 Nov; 4(11):750-3. PubMed ID: 21252454
[TBL] [Abstract][Full Text] [Related]
2. Reasons for modification of generic highly active antiretroviral therapeutic regimens among patients in southern India.
Kumarasamy N; Vallabhaneni S; Cecelia AJ; Yepthomi T; Balakrishnan P; Saghayam S; Flanigan TP; Carpenter CC; Solomon S; Mayer KH
J Acquir Immune Defic Syndr; 2006 Jan; 41(1):53-8. PubMed ID: 16340473
[TBL] [Abstract][Full Text] [Related]
3. Spectrum of adverse events after generic HAART in southern Indian HIV-infected patients.
Kumarasamy N; Venkatesh KK; Cecelia AJ; Devaleenal B; Lai AR; Saghayam S; Balakrishnan P; Yepthomi T; Poongulali S; Flanigan TP; Solomon S; Mayer KH
AIDS Patient Care STDS; 2008 Apr; 22(4):337-44. PubMed ID: 18422462
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of generic fixed-dose combinations of highly active antiretroviral therapy for treatment of HIV infection in India.
Pujari SN; Patel AK; Naik E; Patel KK; Dravid A; Patel JK; Mane AA; Bhagat S
J Acquir Immune Defic Syndr; 2004 Dec; 37(5):1566-9. PubMed ID: 15577409
[TBL] [Abstract][Full Text] [Related]
5. Generic fixed-dose combination antiretroviral treatment in resource-poor settings: multicentric observational cohort.
Calmy A; Pinoges L; Szumilin E; Zachariah R; Ford N; Ferradini L;
AIDS; 2006 May; 20(8):1163-9. PubMed ID: 16691068
[TBL] [Abstract][Full Text] [Related]
6. Changes in antioxidant profile among HIV-infected individuals on generic highly active antiretroviral therapy in southern India.
Sundaram M; Saghayam S; Priya B; Venkatesh KK; Balakrishnan P; Shankar EM; Murugavel KG; Solomon S; Kumarasamy N
Int J Infect Dis; 2008 Nov; 12(6):e61-6. PubMed ID: 18621564
[TBL] [Abstract][Full Text] [Related]
7. Randomized, open-label, comparative trial to evaluate the efficacy and safety of three antiretroviral drug combinations including two nucleoside analogues and nevirapine for previously untreated HIV-1 Infection: the OzCombo 2 study.
French M; Amin J; Roth N; Carr A; Law M; Emery S; Drummond F; Cooper D;
HIV Clin Trials; 2002; 3(3):177-85. PubMed ID: 12032876
[TBL] [Abstract][Full Text] [Related]
8. Tenofovir or zidovudine in three-drug combination therapy with one nucleoside reverse transcriptase inhibitor and one non-nucleoside reverse transcriptase inhibitor for initial treatment of HIV infection in antiretroviral-naïve individuals.
Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Oct; (10):CD008740. PubMed ID: 20927777
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
10. Comparative durability of nevirapine versus efavirenz in first-line regimens during the first year of initiating antiretroviral therapy among Swaziland HIV-infected adults.
Takuva S; Evans D; Zuma K; Okello V; Louwagie G
Pan Afr Med J; 2013; 15():5. PubMed ID: 23847702
[TBL] [Abstract][Full Text] [Related]
11. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection.
Siegfried N; van der Merwe L; Brocklehurst P; Sint TT
Cochrane Database Syst Rev; 2011 Jul; (7):CD003510. PubMed ID: 21735394
[TBL] [Abstract][Full Text] [Related]
12. Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naïve individuals.
Mbuagbaw LC; Irlam JH; Spaulding A; Rutherford GW; Siegfried N
Cochrane Database Syst Rev; 2010 Dec; (12):CD004246. PubMed ID: 21154355
[TBL] [Abstract][Full Text] [Related]
13. An antiretroviral regimen containing 6 months of stavudine followed by long-term zidovudine for first-line HIV therapy is optimal in resource-limited settings: a prospective, multicenter study in China.
Li T; Guo F; Li Y; Zhang C; Han Y; Lye W; He Y; Lu H; Xie J; Huang A; Li Y; Tang X; Wang H; Zhang T; Gao G; Lei J; Zhang X; Wu X; Sun Y; Bai J; Luo L; Wang H
Chin Med J (Engl); 2014; 127(1):59-65. PubMed ID: 24384425
[TBL] [Abstract][Full Text] [Related]
14. [Safety study of 52-week highly active antiretroviral therapy in 198 HIV/AIDS Chinese patients].
Li WJ; Dai Y; Han Y; Qiu ZF; Xie J; Zuo LY; Li YL; Li TS
Zhonghua Yi Xue Za Zhi; 2011 May; 91(19):1318-22. PubMed ID: 21756757
[TBL] [Abstract][Full Text] [Related]
15. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1.
Krogstad P; Lee S; Johnson G; Stanley K; McNamara J; Moye J; Jackson JB; Aguayo R; Dieudonne A; Khoury M; Mendez H; Nachman S; Wiznia A;
Clin Infect Dis; 2002 Apr; 34(7):991-1001. PubMed ID: 11880966
[TBL] [Abstract][Full Text] [Related]
16. Adverse drug reactions to nonnucleoside reverse transcriptase inhibitor-based antiretroviral regimen: a 24-week prospective study.
Jena A; Sachdeva RK; Sharma A; Wanchu A
J Int Assoc Physicians AIDS Care (Chic); 2009; 8(5):318-22. PubMed ID: 19721097
[TBL] [Abstract][Full Text] [Related]
17. Hepatotoxicity from first line antiretroviral therapy: an experience from a resource limited setting.
Kalyesubula R; Kagimu M; Opio KC; Kiguba R; Semitala CF; Schlech WF; Katabira ET
Afr Health Sci; 2011 Mar; 11(1):16-23. PubMed ID: 21572852
[TBL] [Abstract][Full Text] [Related]
18. A comparison of stavudine plus lamivudine versus zidovudine plus lamivudine in combination with indinavir in antiretroviral naive individuals with HIV infection: selection of thymidine analog regimen therapy (START I).
Squires KE; Gulick R; Tebas P; Santana J; Mulanovich V; Clark R; Yangco B; Marlowe SI; Wright D; Cohen C; Cooley T; Mauney J; Uffelman K; Schoellkopf N; Grosso R; Stevens M
AIDS; 2000 Jul; 14(11):1591-600. PubMed ID: 10983646
[TBL] [Abstract][Full Text] [Related]
19. Nevirapine plus efavirenz plus didanosine: a simple, safe, and effective once-daily regimen for patients with HIV infection.
Jordan WC; Jefferson R; Yemofio F; Tolbert L; Conlon V; Carroll H; Green DC; Green A; Green R
J Natl Med Assoc; 2003 Dec; 95(12):1152-7. PubMed ID: 14717471
[TBL] [Abstract][Full Text] [Related]
20. Morphological and metabolic components of lipodystrophy in various nevirapine-based highly active antiretroviral therapy (HAART) regimens: a cross-sectional, observational study.
Guaraldi G; Zona S; Orlando G; Carli F; Stentarelli C; Luzi K; Garlassi E; Menozzi M; Bagni P; Adorni F
Clin Drug Investig; 2011 Nov; 31(11):759-67. PubMed ID: 21919542
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
